Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

BMS Says Cancer Drug Hit Goal in Study

June 24, 2014 7:23 pm | News | Comments

Bristol-Myers said Tuesday that its skin cancer drug nivolumab worked in a late-stage clinical trial, leading the drugmaker to end the study early. Bristol-Myers said patients treated with nivolumab lived longer than patients who received only chemotherapy. Read more...


First GI Microbiome Modulator Improves Blood Sugar

June 24, 2014 2:52 pm | News | Comments

In adults with prediabetes, a new drug that alters microbial populations and their environment in the gastrointestinal (GI) tract improves glucose tolerance — the body’s response to consuming carbohydrates — after four weeks of treatment and without a change in diet. Read more...


U.S. Patent Office Grants Allowance for Advaxis Cancer Immunotherapy Patent Applications

June 24, 2014 2:41 pm | News | Comments

Advaxis Inc., a clinical-stage biotechnology company developing cancer immunotherapies, has received notice of allowance from the United States Patent and Trademark Office (USPTO) on two patents covering the composition and methods of use for ADXS-cHER2. Read more...


CF Foundation Applauds Positive Results of Ivacaftor, Lumacaftor Combo

June 24, 2014 2:36 pm | News | Comments

The Cystic Fibrosis Foundation applauds the successful results - significant improvements in lung function and other key measures of the disease - of Phase 3 studies of ivacaftor (Kalydeco) in combination with lumacaftor (VX-809) for people with two copies of the F508del mutation of cystic fibrosis (CF). Read more...


Stem Cells Form Light-Sensitive 3-D Retinal Tissue

June 24, 2014 2:29 pm | by Carol Torgan, Ph.D. | News | Comments

Researchers led by Drs. Xiufeng Zhong and M. Valeria Canto-Soler at Johns Hopkins University induced human stem cells to create a 3-D retina structure that responds to light. The finding may aid the study of eye diseases and could eventually lead to new therapies. Read more...


First Large-Scale, Real-World Evidence Links Low LDL-P and Reduced CVD Risk

June 24, 2014 2:21 pm | News | Comments

LipoScience Inc. announced the publication of the first large-scale real world study - sponsored by LipoScience and jointly designed by LipoScience and HealthCore - evidencing a link between low LDL-P and reduced cardiovascular disease (CVD) risk. Read more...


Pharma Industry Turns the Corner

June 24, 2014 2:13 pm | News | Comments

Record breaking new drug approvals, a hefty product pipeline and dramatically improved R&D productivity that has kept expenditure growth below sales growth prove that the industry is turning a new corner according to Evaluate's "World Preview 2014, Outlook to 2020" report. Read more...


FDA Lifts Partial Hold on BRI’s Study of Glioma Drug

June 24, 2014 11:29 am | News | Comments

The Burzynski Research Institute Inc. (BRI) announced that U.S. Food and Drug Administration (FDA) has notified the company that its partial clinical hold on its IND for Antineoplastons A10/AS2-1 Injections has been lifted, and it may initiate its planned Phase 3 study in newly diagnosed diffuse, intrinsic, brainstem glioma. Read more...


EMD Serono, Mersana to Develop Next-Gen ADCs

June 24, 2014 11:23 am | News | Comments

EMD Serono Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Mersana Therapeutics Inc., Cambridge, Mass., U.S., announced an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs), which are composed of an antibody linked to cytotoxic drugs. Read more...


Researchers Find Fatal Cellular Malfunction in Huntington’s

June 24, 2014 11:16 am | by Michael C. Purdy | News | Comments

Researchers believe they have learned how mutations in the gene that causes Huntington’s disease kill brain cells, a finding that could open new opportunities for treating the fatal disorder, which affects five to seven people out of every 100,000. Read more...


Bayer, Dimension Collaborate on Hemophilia Gene Therapy

June 24, 2014 11:05 am | News | Comments

Bayer HealthCare and Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy treatments for rare diseases, have entered into a collaboration for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. Read more...


Abbott to Acquire Russian Pharma Co Veropharm

June 24, 2014 11:00 am | News | Comments

Abbott announced a definitive agreement to acquire Veropharm, a leading Russian pharmaceutical manufacturer, having had a presence in Russia for nearly 40 years and being committed to growing global health care markets and capabilities. Read more...


UK Guidelines Unfairly Exclude Prisoners from Clinical Research

June 24, 2014 10:52 am | News | Comments

Prisoners are being unfairly excluded from taking part in potentially beneficial clinical research, on the grounds that it would be too difficult and expensive to do so, indicates a study published online in the Journal of Medical Ethics. Read more...


Regado’s Anticoagulation System Suppresses Thrombin

June 23, 2014 2:30 pm | News | Comments

Regado Biosciences Inc., a biopharmaceutical company focused on the discovery and development of actively controllable aptamer therapeutics for the acute care setting, announced the publication in the Journal of Thrombosis and Thrombolysis of data from a single escalating-dose Phase 1 clinical trial of the REG2 anticoagulation system. Read more...


Rhythm’s Obesity Drug Increases Energy Expenditure

June 23, 2014 2:25 pm | News | Comments

Rhythm announced the presentation of results from a clinical trial that evaluated the effect of RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, on resting energy expenditure in obese subjects, indicating that RM-493 increased resting energy expenditure significantly. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.